Image Sourced ShutteerStock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Bod Australia spiked more than 35 per cent today after signing a deal with H&H subsidiary, NewH2
  • The contract gives H&H the exclusive rights to sell, promote, market and distribute Bod products worldwide under a new brand
  • Bod will retain full rights to commercialise its medicinal cannabidiol (CBD) extracts for pharmaceutical purposes
  • NewH2 will invest $5.5 million into Bod and make a upfront cash payment of $1.5 million
  • The companies will initially focus on products for the UK, USA, France, Italy and the Netherlands.

Shares in medicinal hemp company Bod Australia spiked more than 35 per cent today after the company signed a deal with Chinese investment company NewH2.

NewH2 is a subsidiary of Hong Kong-based healthcare company H&H Global. The new contract gives H&H the exclusive rights to sell, promote, market and distribute Bod products worldwide under a new brand.

Bod, however, will retain full rights to commercialise its medicinal cannabidiol (CBD) extracts for pharmaceutical purposes, and plans to keep building its business in Australia and around the world.

Bod will also receive a royalty on net sales, and a cost plus margin for the supply of its finished formulas and extracts. On top of this, H&H and Bod will become development partners as part of the deal — meaning they’ll work together on future development initiatives for Bod’s CBD extract.

CBD is extracted from hemp, and Bod management says its CBD products are non-addictive, non-psychoactive and comply with all local laws and regulations in relevant markets around the world.

NewH2 will invest $5.5 million into Bod by subscribing for nearly 15 million new Bod shares at 37 cents each. On top of this, Bod will received an upfront cash payment of $1.5 million to help transition into H&H.

Once all shares have been settled, NewH2 will hold 17.64 per cent of Bod shares and will subsequently be given two seats on the Bod board.

Bod CEO Jo Patterson said the deal is a game changer for the company.

“This agreement provides Bod with financial flexibility and considerable validation of our work to date and strategy of working with best in class operators and partners,” Jo said.

She added that the company is thrilled to have been noticed and chosen as a partner by H&H, which boasts a broad distribution network and a suite of established brands.

“H&H Group is undoubtedly the global leader in supplements and vitamins,” she said.

H&H CEO and Executive Director Laetitia Garnier shared similar sentiments, saying the hemp market — particularly in Australia — has untapped potential.

“We are excited for NewH2 to take this step with Bod Australia and to be investing in this high-growth industry,” Laetitia said.

“Our new partner Bod is leading the way with clinical trials and innovation programs, and together we are well-positioned to grow and to further commercialise Bod’s CBD products in different global markets,” she said.

H&H develops nutrition and care products and is listed on the Hong Kong Stock Exchange. Bod will now be support H&H in the innovation and product development of nutraceutical CBD products, including skincare.

The companies will initially focus on products for the UK, USA, France, Italy and the Netherlands.

Bod shares are currently up 34.29 per cent from last close, trading for 47 cents each within a $32.61 million market cap.

BDA by the numbers
More From The Market Herald
The Market Herald Video

" Proteomics International Laboratories (ASX:PIQ) signs binding LOI with Sonic Healthcare USA

Proteomics International Laboratories (ASX:PIQ) signs a binding letter of intent to introduce PromarkerD to the US.
The Market Herald Video

" Dimerix (ASX:DXB) submits new patent family application for DMX-700

Dimerix (ASX:DXB) has submitted a new patent family application for its flagship DMX-700 used to treat…
The Market Herald Video

" Mesoblast (ASX:MSB) raises US$45m for lead products

Mesoblast (ASX:MSB) completes its private placement which raised US$45 million (A$64.5 million).
The Market Herald Video

" Imugene (ASX:IMU) sees “positive signs” from lung cancer trial, presents data at 2022 world conference

Imugene (ASX:IMU) presents new data from its PD1-Vaxx trial in non-small cell lung cancer patients at…